

Table 23 Spontaneous motor activity of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene					
	0	45	180		720			
Number of males	6	6	6		6			
<b>Ambulatory counts</b>								
Minutes after administration								
10	573 ± 493		645 ± 517		1048 ± 535		1007 ± 568	
20	242 ± 278		317 ± 322		240 ± 232		249 ± 285	
30	110 ± 142		174 ± 220		115 ± 145		292 ± 276	
40	64 ± 65		57 ± 61		81 ± 95		167 ± 174	
50	167 ± 313		94 ± 87		87 ± 101		100 ± 173	
60	93 ± 136		59 ± 76		112 ± 144		106 ± 110	
Total	1249 ± 1221		1346 ± 1003		1682 ± 874		1921 ± 1354	
<b>Vertical counts</b>								
Minutes after administration								
10	28 ± 14		37 ± 28		42 ± 21		61 ± 34	
20	14 ± 12		19 ± 16		13 ± 11		23 ± 27	
30	7 ± 11		14 ± 17		12 ± 21		25 ± 20	
40	2 ± 3		9 ± 19		4 ± 6		14 ± 15	
50	2 ± 4		11 ± 21		6 ± 9		16 ± 24	
60	4 ± 6		11 ± 19		5 ± 8		15 ± 19	
Total	57 ± 30		101 ± 111		82 ± 43		154 ± 129	

Each value shows mean ± S.D.

Table 24 Spontaneous motor activity of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene					
	0	45	180		720			
Number of females	6	6	6		6			
<b>Ambulatory counts</b>								
Minutes after administration								
10	1837 ± 925		1576 ± 767		1338 ± 649		1516 ± 1161	
20	672 ± 553		277 ± 212		225 ± 388		659 ± 574	
30	172 ± 189		92 ± 123		132 ± 249		395 ± 481	
40	355 ± 451		26 ± 57		108 ± 173		233 ± 336	
50	320 ± 520		154 ± 274		75 ± 130		585 ± 1192	
60	217 ± 177		174 ± 192		100 ± 203		215 ± 325	
Total	3572 ± 1905		2298 ± 1139		1978 ± 1005		3601 ± 3674	
<b>Vertical counts</b>								
Minutes after administration								
10	33 ± 12		36 ± 16		31 ± 19		34 ± 14	
20	13 ± 9		9 ± 8		4 ± 8		13 ± 8	
30	2 ± 3		3 ± 3		4 ± 7		7 ± 6	
40	6 ± 6		1 ± 3		3 ± 4		4 ± 8	
50	6 ± 7		4 ± 7		1 ± 2		7 ± 12	
60	8 ± 12		3 ± 3		3 ± 7		4 ± 9	
Total	67 ± 29		56 ± 25		46 ± 27		70 ± 44	

Each value shows mean ± S.D.

Table 25-1 Urinary examination of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
	0	45	180	720	
Number of males	6	6	6	6	
Volume (mL): Mean ± S.D.	9.2 ± 1.7	10.9 ± 3.2	10.1 ± 1.8	25.6 ± 5.0 **	
Specific gravity: Mean ± S.D.	1.059 ± 0.012	1.053 ± 0.010	1.052 ± 0.008	1.031 ± 0.004 **	
Color					
Light yellow	6	6	6	6	
pH					
8.0	0	0	1	0	
8.5	1	3	2	4	
9.0	5	3	3	2	
Protein					
10~20 mg/dL	0	3	1	1	
30 mg/dL	3	0	2	4	
100 mg/dL	3	3	3	1	
Glucose					
Negative	6	6	6	6	
Ketone body					
Negative	4	6	3	6	
Slight	2	0	3	0	
Bilirubin					
Negative	6	6	6	6	
Occult blood					
Negative	5	4	4	5	
Trace	1	2	1	1	
Moderate	0	0	1	0	
Urobilinogen					
Normal	5	6	6	6	
1 mg/dL	1	0	0	0	

Significantly different from control group (\*\*: P<0.01).

Table 25-2 Urinary examination of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control	I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
		45	180	720
Number of males	6	6	6	6
Urinary sediments				
Epithelial cells				
0~20 cells/100 fields	6	6	6	5
101~200 cells/100fields	0	0	0	1
Erythrocytes				
0~20 cells/100 fields	6	6	5	6
21~100 cells/100 fields	0	0	1	0
Leukocytes				
0~20 cells/100 fields	6	6	6	6
Casts				
Not observed	6	6	6	6
Crystals				
Not observed	3	4	1	1
Observed	3	2	5	5

Table 26-1 Urinary examination of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	Control		I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
	mg/kg	0	45	180	720
Number of females		6	6	6	6
Volume (mL): Mean ± S.D.	30.1 ± 5.9		26.6 ± 8.6	37.5 ± 4.8	41.6 ± 17.3
Specific gravity: Mean ± S.D.	1.024 ± 0.003		1.028 ± 0.007	1.023 ± 0.003	1.022 ± 0.007
Color					
Light yellow		6	6	6	6
pH					
5.5		0	0	1	0
6.0		0	0	1	1
6.5		1	2	1	0
7.0		1	2	1	1
7.5		2	0	2	0
8.0		1	0	0	1
8.5		0	2	0	3
9.0		1	0	0	0
Protein					
Negative		5	3	4	2
10~20 mg/dL		1	2	2	3
30 mg/dL		0	1	0	1
Glucose					
Negative		6	6	6	6
Ketone body					
Negative		6	6	6	6
Bilirubin					
Negative		6	6	6	6
Occult blood					
Negative		6	5	6	6
Slight		0	1	0	0
Urobilinogen					
Normal		6	6	6	6

Table 26-2 Urinary examination of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control	I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
		45	180	720
Number of females	6	6	6	6
Urinary sediments				
Epithelial cells				
0~20 cells/100 fields	6	6	6	6
Erythrocytes				
0~20 cells/100 fields	6	6	6	6
Leukocytes				
0~20 cells/100 fields	6	6	6	6
Casts				
Not observed	6	6	6	6
Crystals				
Not observed	1	3	5	4
Observed	5	3	1	2

Table 27-1 Urinary examination of male rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
	0	45	180	720	
Number of males	6	6	6	6	
Volume (mL): Mean ± S.D.	12.1 ± 5.9	14.0 ± 4.7	17.1 ± 4.8	17.8 ± 3.5	
Specific gravity: Mean ± S.D.	1.053 ± 0.014	1.052 ± 0.013	1.047 ± 0.010	1.049 ± 0.010	
Color					
Light yellow	6	6	6	6	
pH					
8.5	1	4	4	5	
9.0	5	2	2	1	
Protein					
10~20 mg/dL	1	1	0	0	
30 mg/dL	2	3	3	2	
100 mg/dL	2	2	2	4	
300 mg/dL	1	0	0	0	
1000 mg/dL	0	0	1	0	
Glucose					
Negative	6	6	6	6	
Ketone body					
Negative	3	5	4	5	
Slight	3	1	2	1	
Bilirubin					
Negative	6	6	6	6	
Occult blood					
Negative	6	6	6	6	
Urobilinogen					
Normal	5	6	6	6	
1 mg/dL	1	0	0	0	

Table 27-2 Urinary examination of male rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control	I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
		45	180	720
Number of males	6	6	6	6
Urinary sediments				
Epithelial cells				
0~20 cells/100 fields	6	6	6	6
Erythrocytes				
0~20 cells/100 fields	6	6	6	6
Leukocytes				
0~20 cells/100 fields	6	6	6	6
Casts				
Not observed	6	6	6	6
Crystals				
Not observed	4	4	3	0
Observed	2	2	3	6

Table 28-1 Urinary examination of female rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene	
	0		180	720
Number of females	6		6	5
Volume (mL): Mean ± S.D.	14.2 ± 4.7		12.8 ± 6.2	12.7 ± 4.9
Specific gravity: Mean ± S.D.	1.045 ± 0.014		1.047 ± 0.015	1.041 ± 0.009
Color				
Light yellow	6		6	5
pH				
7.5	0		0	1
8.0	0		1	1
8.5	4		3	2
9.0	2		2	1
Protein				
Negative	2		2	0
10~20 mg/dL	2		2	2
30 mg/dL	2		2	0
100 mg/dL	0		0	3
Glucose				
Negative	6		6	5
Ketone body				
Negative	6		5	5
Slight	0		1	0
Bilirubin				
Negative	6		6	5
Occult blood				
Negative	6		5	4
Trace	0		1	1
Urobilinogen				
Normal	6		5	5
1 mg/dL	0		1	0

Table 28-2 Urinary examination of female rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	Control	I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene	
mg/kg	0	180	720
Number of females	6	6	4
Urinary sediments			
Epithelial cells			
0~20 cells/100 fields	6	6	5
Erythrocytes			
0~20 cells/100 fields	6	6	5
Leukocytes			
0~20 cells/100 fields	6	6	5
Casts			
Not observed	6	6	5
Crystals			
Not observed	2	3	1
Observed	4	3	4

Table 29 Hematological examination of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene			
	0		45	180	720	
Number of males	6		6	6	6	
RBC (10 <sup>6</sup> /μL)	830 ± 25		836 ± 21	820 ± 21	802 ± 26	
HGB (g/dL)	15.5 ± 0.5		15.5 ± 0.3	15.3 ± 0.5	15.0 ± 0.6	
HCT (%)	46.1 ± 1.5		45.8 ± 0.9	45.6 ± 2.1	44.5 ± 1.6	
MCV (fL)	55.6 ± 0.7		54.8 ± 2.3	55.5 ± 2.0	55.5 ± 0.8	
MCH (pg)	18.7 ± 0.4		18.5 ± 0.7	18.7 ± 0.5	18.7 ± 0.3	
MCHC (g/dL)	33.6 ± 0.5		33.8 ± 0.4	33.7 ± 0.5	33.6 ± 0.6	
PLT (10 <sup>3</sup> /μL)	96.9 ± 8.5		96.9 ± 8.2	101.9 ± 8.0	105.3 ± 8.0	
RET (%)	24 ± 9		25 ± 2	23 ± 4	23 ± 7	
PT (sec.)	18.7 ± 2.5		22.6 ± 3.2	30.3 ± 4.5 **	28.3 ± 6.6 **	
APTT (sec.)	23.4 ± 2.5		26.9 ± 2.3	34.7 ± 4.5 **	38.7 ± 4.8 **	
Fbg (mg/dL)	219.4 ± 14.1		217.9 ± 10.9	233.1 ± 18.9	252.4 ± 16.9 **	
WBC (10 <sup>3</sup> /μL)	74 ± 17		62 ± 17	73 ± 20	64 ± 20	
Differential leukocyte (%)						
Lymphocyte	84.8 ± 6.3		85.3 ± 5.7	85.8 ± 5.1	84.8 ± 4.1	
Neutrophil	13.8 ± 5.8		13.7 ± 5.5	13.0 ± 4.9	14.5 ± 4.1	
Eosinophil	0.7 ± 0.8		0.3 ± 0.8	0.3 ± 0.5	0.5 ± 0.5	
Basophil	0.0 ± 0.0		0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	
Monocyte	0.7 ± 0.8		0.7 ± 0.5	0.8 ± 0.4	0.2 ± 0.4	

Each value shows mean ± S.D.

Significantly different from control group (\*\*: P<0.01).

Table 30 Hematological examination of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene			
	0		45	180	720	
Number of females	6		6	6	6	
RBC (10 <sup>6</sup> /μL)	749 ± 21		752 ± 52	702 ± 28	679 ± 66 *	
HGB (g/dL)	14.7 ± 0.4		14.7 ± 0.8	14.0 ± 0.3	13.6 ± 1.0	
HCT (%)	43.4 ± 1.4		43.2 ± 2.4	40.7 ± 1.1	40.1 ± 3.1 *	
MCV (fL)	57.9 ± 1.4		57.5 ± 1.5	58.1 ± 1.6	59.2 ± 2.1	
MCH (pg)	19.7 ± 0.6		19.6 ± 0.7	19.9 ± 0.8	20.1 ± 0.8	
MCHC (g/dL)	34.0 ± 0.5		34.1 ± 0.3	34.3 ± 0.7	34.0 ± 0.4	
PLT (10 <sup>3</sup> /μL)	109.7 ± 10.9		92.8 ± 26.5	105.6 ± 6.2	130.4 ± 15.1	
RET (%)	55 ± 9		51 ± 8	58 ± 12	64 ± 11	
PT (sec.)	16.2 ± 0.6		15.4 ± 0.2 *	15.0 ± 0.5 **	14.7 ± 0.6 **	
APTT (sec.)	16.9 ± 1.9		18.4 ± 0.5	18.1 ± 1.2	21.5 ± 1.8 **	
Fbg (mg/dL)	231.2 ± 12.5		237.5 ± 61.8	285.6 ± 82.6	210.4 ± 23.5	
WBC (10 <sup>3</sup> /μL)	39 ± 8		49 ± 8	61 ± 19 *	56 ± 18	
Differential leukocyte (%)						
Lymphocyte	85.2 ± 7.2		84.0 ± 7.1	81.3 ± 9.1	87.2 ± 1.7	
Neutrophil	13.8 ± 6.4		14.7 ± 6.7	17.7 ± 9.2	12.2 ± 1.7	
Eosinophil	0.5 ± 0.8		0.3 ± 0.5	0.3 ± 0.5	0.2 ± 0.4	
Basophil	0.0 ± 0.0		0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	
Monocyte	0.5 ± 0.5		1.0 ± 0.6	0.7 ± 0.8	0.5 ± 0.5	

Each value shows mean ± S.D.

Significantly different from control group (\*: P<0.05, \*\*: P<0.01).

Table 31 Hematological examination of male rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene			
	0	45	180	720		
Number of males	6	6	6	6		
RBC (10 <sup>6</sup> /μL)	861 ± 21	854 ± 11	851 ± 39	846 ± 53		
HGB (g/dL)	15.7 ± 0.5	15.5 ± 0.6	15.6 ± 0.6	15.1 ± 0.7		
HCT (%)	46.4 ± 1.8	45.7 ± 1.3	46.0 ± 2.1	44.9 ± 2.5		
MCV (fL)	53.9 ± 1.7	53.6 ± 1.3	54.1 ± 1.1	53.1 ± 0.7		
MCH (pg)	18.2 ± 0.5	18.1 ± 0.6	18.3 ± 0.3	17.9 ± 0.3		
MCHC (g/dL)	33.8 ± 0.2	33.8 ± 0.5	33.9 ± 0.4	33.6 ± 0.4		
PLT (10 <sup>3</sup> /μL)	100.7 ± 13.6	95.1 ± 16.9	97.1 ± 6.7	106.8 ± 10.0		
RET (%)	26 ± 5	26 ± 5	25 ± 5	34 ± 9		
PT (sec.)	19.3 ± 3.2	17.5 ± 1.6	17.6 ± 1.9	22.2 ± 3.5		
APTT (sec.)	23.5 ± 1.6	22.2 ± 1.6	22.3 ± 1.4	24.4 ± 1.8		
Fbg (mg/dL)	196.6 ± 7.9	205.4 ± 17.4	212.9 ± 10.6	199.8 ± 10.0		
WBC (10 <sup>3</sup> /μL)	57 ± 19	59 ± 19	61 ± 11	44 ± 7		
Differential leukocyte (%)						
Lymphocyte	87.5 ± 4.1	87.5 ± 5.0	87.3 ± 5.5	84.2 ± 6.8		
Neutrophil	12.0 ± 4.1	11.2 ± 4.4	11.8 ± 5.2	15.2 ± 6.2		
Eosinophil	0.2 ± 0.4	0.7 ± 0.8	0.3 ± 0.5	0.3 ± 0.5		
Basophil	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0		
Monocyte	0.3 ± 0.5	0.7 ± 0.5	0.5 ± 0.5	0.3 ± 0.5		

Each value shows mean ± S.D.

Table 32 Hematological examination of female rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene			
	0	6	180	6	720	5
Number of females		6		6		5
RBC (10 <sup>6</sup> /μL)	785 ± 20		800 ± 31		796 ± 26	
HGB (g/dL)	15.2 ± 0.6		15.2 ± 0.3		14.9 ± 0.5	
HCT (%)	43.7 ± 1.2		44.1 ± 1.2		43.4 ± 1.1	
MCV (fL)	55.7 ± 0.9		55.2 ± 1.2		54.6 ± 1.8	
MCH (pg)	19.4 ± 0.4		19.0 ± 0.6		18.8 ± 0.9	
MCHC (g/dL)	34.9 ± 0.4		34.5 ± 0.5		34.4 ± 0.6	
PLT (10 <sup>3</sup> /μL)	103.0 ± 12.2		106.8 ± 12.6		105.4 ± 11.0	
RET (%)	21 ± 2		24 ± 6		23 ± 5	
PT (sec.)	15.7 ± 0.5		15.1 ± 0.9		15.4 ± 0.1	
APTT (sec.)	18.3 ± 1.4		17.6 ± 0.9		18.4 ± 0.7	
Fbg (mg/dL)	169.0 ± 11.6		162.9 ± 15.5		175.8 ± 14.4	
WBC (10 <sup>3</sup> /μL)	34 ± 9		31 ± 6		34 ± 12	
Differential leukocyte (%)						
Lymphocyte	83.3 ± 7.1		84.8 ± 8.0		83.2 ± 4.6	
Neutrophil	15.7 ± 6.8		13.3 ± 7.8		15.6 ± 4.9	
Eosinophil	0.7 ± 0.5		1.2 ± 1.2		0.6 ± 0.9	
Basophil	0.0 ± 0.0		0.0 ± 0.0		0.0 ± 0.0	
Monocyte	0.3 ± 0.8		0.7 ± 0.8		0.6 ± 0.5	

Each value shows mean ± S.D.

Table 33 Blood chemical examination of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
	0	45	180	720	
Number of males	6	6	6	6	
AST (IU/L)	114.8 ± 89.5	72.7 ± 11.7	65.1 ± 9.5	61.5 ± 8.3 **	
ALT (IU/L)	49.2 ± 47.5	33.2 ± 9.2	37.4 ± 14.7	38.9 ± 10.9	
ALP (IU/L)	365.8 ± 52.5	368.7 ± 78.6	357.8 ± 36.7	389.0 ± 131.6	
γ-GTP (IU/L)	0.53 ± 0.17	0.33 ± 0.18	1.39 ± 0.71	2.62 ± 0.87 **	
TP (g/dL)	5.59 ± 0.17	5.62 ± 0.23	5.86 ± 0.18	6.40 ± 0.40 **	
Alb (g/dL)	2.76 ± 0.12	2.80 ± 0.15	2.92 ± 0.13	3.29 ± 0.20 **	
A/G	0.98 ± 0.04	0.99 ± 0.05	1.00 ± 0.06	1.06 ± 0.04 *	
T-Bil (mg/dL)	0.13 ± 0.05	0.09 ± 0.04	0.15 ± 0.01	0.27 ± 0.05 *	
UN (mg/dL)	14.8 ± 2.4	13.2 ± 1.4	14.6 ± 2.0	14.3 ± 2.2	
CRE (mg/dL)	0.30 ± 0.05	0.28 ± 0.03	0.27 ± 0.03	0.26 ± 0.01	
Glu (mg/dL)	127.3 ± 9.4	118.7 ± 13.0	121.8 ± 5.5	114.8 ± 12.5	
T-Cho (mg/dL)	55.2 ± 12.4	55.5 ± 11.6	65.3 ± 9.9	125.9 ± 34.2 **	
TG (mg/dL)	21.0 ± 5.2	35.8 ± 16.7	15.1 ± 6.2	13.2 ± 6.1	
Na (mEq/L)	144.5 ± 1.3	144.9 ± 1.0	144.6 ± 1.6	144.4 ± 1.2	
K (mEq/L)	4.37 ± 0.20	4.39 ± 0.20	4.03 ± 0.16 *	4.29 ± 0.24	
Cl (mEq/L)	106.2 ± 1.2	105.8 ± 1.0	105.2 ± 1.8	104.0 ± 1.1 *	
Ca (mg/dL)	9.5 ± 0.3	9.6 ± 0.4	10.0 ± 0.2 *	10.3 ± 0.4 **	
IP (mg/dL)	6.6 ± 0.6	6.6 ± 0.8	6.3 ± 0.5	6.2 ± 0.4	

Each value shows mean ± S.D.

Significantly different from control group (\*: P<0.05, \*\*: P<0.01).

Table 34 Blood chemical examination of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene			
	0	45	180	720		
Number of females	6	6	6	6		
AST (IU/L)	82.0 ± 18.1	91.1 ± 15.5	104.3 ± 25.0	110.5 ± 54.4		
ALT (IU/L)	23.2 ± 3.7	27.3 ± 4.6	25.2 ± 0.7	54.6 ± 63.7		
ALP (IU/L)	238.6 ± 39.4	178.0 ± 17.9	215.9 ± 92.8	209.8 ± 67.9		
γ-GTP (IU/L)	0.49 ± 0.04	1.29 ± 1.41	1.07 ± 0.76	3.42 ± 1.48 **		
TP (g/dL)	6.09 ± 0.21	6.30 ± 0.41	6.60 ± 0.19 *	6.64 ± 0.44 *		
Alb (g/dL)	3.14 ± 0.12	3.14 ± 0.26	3.07 ± 0.23	3.41 ± 0.24		
A/G	1.07 ± 0.08	1.00 ± 0.08	0.88 ± 0.15 *	1.06 ± 0.07		
T-Bil (mg/dL)	0.14 ± 0.02	0.14 ± 0.03	0.15 ± 0.02	0.20 ± 0.04 *		
UN (mg/dL)	17.0 ± 2.4	19.3 ± 2.6	21.7 ± 7.1	16.5 ± 1.8		
CRE (mg/dL)	0.33 ± 0.03	0.36 ± 0.05	0.36 ± 0.05	0.33 ± 0.03		
Glu (mg/dL)	120.7 ± 10.6	112.4 ± 5.7	105.2 ± 8.0	93.2 ± 18.6 **		
T-Cho (mg/dL)	74.2 ± 13.6	60.4 ± 8.4	64.0 ± 10.2	76.2 ± 21.5		
TG (mg/dL)	21.1 ± 7.0	27.5 ± 9.8	31.3 ± 9.3	30.7 ± 10.4		
Na (mEq/L)	142.2 ± 0.4	141.1 ± 1.1	138.2 ± 4.6	141.8 ± 1.5		
K (mEq/L)	4.07 ± 0.38	4.10 ± 0.24	4.32 ± 0.28	4.32 ± 0.29		
Cl (mEq/L)	105.4 ± 0.7	105.0 ± 1.4	101.2 ± 3.7 *	103.8 ± 1.4		
Ca (mg/dL)	10.6 ± 0.3	10.9 ± 0.3	11.0 ± 0.5	10.8 ± 0.4		
IP (mg/dL)	6.7 ± 0.7	6.7 ± 0.6	7.0 ± 0.5	6.4 ± 0.9		

Each value shows mean ± S.D.

Significantly different from control group (\*: P<0.05, \*\*: P<0.01).

Table 35 Blood chemical examination of male rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of  
1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
	0	45	180	720	
Number of males	6	6	6	6	
AST (IU/L)	89.7 ± 11.8	84.1 ± 6.1	87.9 ± 10.7	78.8 ± 5.0	
ALT (IU/L)	28.1 ± 6.2	29.8 ± 6.5	31.1 ± 5.1	32.1 ± 6.3	
ALP (IU/L)	277.4 ± 49.2	334.8 ± 69.2	330.1 ± 72.8	278.1 ± 72.4	
γ-GTP (IU/L)	0.42 ± 0.15	0.45 ± 0.17	0.61 ± 0.21	0.81 ± 0.27 **	
TP (g/dL)	5.46 ± 0.28	5.38 ± 0.22	5.69 ± 0.16	5.53 ± 0.36	
Alb (g/dL)	2.75 ± 0.08	2.69 ± 0.17	2.90 ± 0.16	2.75 ± 0.15	
A/G	1.02 ± 0.08	1.00 ± 0.07	1.04 ± 0.07	1.00 ± 0.10	
T-Bil (mg/dL)	0.17 ± 0.03	0.15 ± 0.02	0.16 ± 0.02	0.15 ± 0.02	
UN (mg/dL)	17.2 ± 2.8	17.3 ± 2.6	16.5 ± 2.6	16.7 ± 1.6	
CRE (mg/dL)	0.30 ± 0.02	0.30 ± 0.04	0.28 ± 0.02	0.27 ± 0.03	
Glu (mg/dL)	117.6 ± 6.3	140.4 ± 21.1	116.9 ± 6.6	115.5 ± 11.4	
T-Cho (mg/dL)	56.4 ± 12.6	61.5 ± 12.2	68.1 ± 18.3	60.6 ± 16.5	
TG (mg/dL)	35.5 ± 18.6	44.0 ± 38.6	36.9 ± 16.1	28.7 ± 9.4	
Na (mEq/L)	138.1 ± 0.9	138.0 ± 0.9	138.2 ± 1.0	138.0 ± 0.7	
K (mEq/L)	4.26 ± 0.17	4.11 ± 0.18	4.21 ± 0.10	4.30 ± 0.10	
Cl (mEq/L)	100.7 ± 1.2	100.4 ± 0.2	100.6 ± 0.7	100.5 ± 0.6	
Ca (mg/dL)	9.3 ± 0.3	9.3 ± 0.2	9.5 ± 0.2	9.5 ± 0.4	
IP (mg/dL)	6.4 ± 0.5	6.6 ± 0.5	6.5 ± 0.4	6.9 ± 0.7	

Each value shows mean ± S.D.

Significantly different from control group (\*\*: P<0.01).

Table 36 Blood chemical examination of female rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group mg/kg	Control		1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene	
	0		180	720
Number of females	6	6	5	
AST (IU/L)	77.7 ± 9.7		74.4 ± 26.2	70.9 ± 17.3
ALT (IU/L)	25.0 ± 6.0		24.6 ± 4.6	22.3 ± 2.6
ALP (IU/L)	137.1 ± 24.1		127.1 ± 23.5	113.5 ± 14.1
γ-GTP (IU/L)	0.59 ± 0.45		0.59 ± 0.27	0.50 ± 0.36
TP (g/dL)	6.24 ± 0.59		6.43 ± 0.33	6.77 ± 0.29
Alb (g/dL)	3.48 ± 0.37		3.41 ± 0.23	3.71 ± 0.16
A/G	1.26 ± 0.13		1.13 ± 0.07	1.22 ± 0.09
T-Bil (mg/dL)	0.16 ± 0.04		0.15 ± 0.04	0.17 ± 0.03
UN (mg/dL)	18.2 ± 1.3		17.0 ± 1.4	18.5 ± 1.3
CRE (mg/dL)	0.36 ± 0.03		0.34 ± 0.03	0.32 ± 0.03
Glu (mg/dL)	122.6 ± 11.5		123.2 ± 9.2	120.9 ± 13.9
T-Cho (mg/dL)	69.5 ± 12.4		83.8 ± 9.7	99.2 ± 24.4 *
TG (mg/dL)	21.8 ± 11.1		20.3 ± 2.9	25.8 ± 3.9
Na (mEq/L)	133.4 ± 1.3		134.1 ± 1.1	133.4 ± 1.0
K (mEq/L)	3.78 ± 0.36		3.72 ± 0.25	3.71 ± 0.12
Cl (mEq/L)	100.5 ± 0.7		100.1 ± 2.3	97.8 ± 0.9 *
Ca (mg/dL)	9.9 ± 0.6		10.0 ± 0.3	10.4 ± 0.3
IP (mg/dL)	4.6 ± 0.6		5.3 ± 0.6	5.1 ± 0.5

Each value shows mean ± S.D.

Significantly different from control group (\*: P<0.05).

Table 37 Necropsy findings of dead female rats in combined repeat dose and reproductive/developmental toxicity screening test of  
1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene
mg/kg	720
Number of dead females	1
Thymus	
Atrophy	1
Spleen	
Atrophy	1

Table 38 Necropsy findings of dead female rats (recovery group) in combined repeat dose and reproductive/developmental toxicity screening test of  
1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene
mg/kg	720
Number of dead females	1
Thymus	
Atrophy	1
Adrenal	
Enlargement	1

Table 39 Necropsy findings of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	Control	1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
mg/kg	0	45	180	720
Number of males	6	6	6	6
Normal	6	6	6	6

Table 40 Necropsy findings of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of 1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	Control	1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene	
mg/kg	0	45	180
Number of dams	11	12	11
Normal	11	12	11
Number of non-pregnant females	1	0	1
Normal	1	-	1

**Table 41** Necropsy findings of male rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	Control	I,I'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene		
mg/kg	0	45	180	720
Number of males	6	6	6	6
Normal	6	5	6	6
Liver				
Adhesion	0	1	0	0

Table 42 Necropsy findings of female rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of  
1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene by oral administration

Group	Control	1,1'-(1,1-dimethyl-3-methylene-1,3-propanediyl)bisbenzene	
mg/kg	0	180	720
Number of females	6	6	5
Normal	6	6	5